Currently, no ovarian cancer screening test with high sensitivity and specificity exists. In a recent proof-of-concept study published in Nature Biomedical Engineering, a uniquely designed microfluidic nanochip detected low levels of ovarian cancer–associated markers in blood. If validated in large trials, the technology could be used for early detection of the cancer, which is currently diagnosed at late clinical stages in approximately 85% of patients.
Abbasi J. Novel Nanochip Paves Way for Early Ovarian Cancer Detection. JAMA. 2019;321(18):1759. doi:10.1001/jama.2019.5460
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: